JP2011516047A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011516047A5 JP2011516047A5 JP2011502198A JP2011502198A JP2011516047A5 JP 2011516047 A5 JP2011516047 A5 JP 2011516047A5 JP 2011502198 A JP2011502198 A JP 2011502198A JP 2011502198 A JP2011502198 A JP 2011502198A JP 2011516047 A5 JP2011516047 A5 JP 2011516047A5
- Authority
- JP
- Japan
- Prior art keywords
- biological
- vector
- group
- biological vector
- vector according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013598 vector Substances 0.000 claims 38
- 210000004027 cell Anatomy 0.000 claims 13
- 230000003612 virological effect Effects 0.000 claims 8
- 239000013599 cloning vector Substances 0.000 claims 7
- 101150018298 MAX gene Proteins 0.000 claims 6
- 239000013612 plasmid Substances 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 5
- 241000702421 Dependoparvovirus Species 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 4
- 210000002569 neuron Anatomy 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- 229920002307 Dextran Polymers 0.000 claims 2
- 241000713666 Lentivirus Species 0.000 claims 2
- 206010046865 Vaccinia virus infection Diseases 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 210000004507 artificial chromosome Anatomy 0.000 claims 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 2
- 239000001506 calcium phosphate Substances 0.000 claims 2
- 125000002091 cationic group Chemical group 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000004520 electroporation Methods 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 239000002502 liposome Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 238000000520 microinjection Methods 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 241000701161 unidentified adenovirus Species 0.000 claims 2
- 241001529453 unidentified herpesvirus Species 0.000 claims 2
- 241001430294 unidentified retrovirus Species 0.000 claims 2
- 208000007089 vaccinia Diseases 0.000 claims 2
- 239000003981 vehicle Substances 0.000 claims 2
- 230000001413 cellular effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000000185 intracerebroventricular administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000000324 neuroprotective effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI0800957-0 | 2008-04-04 | ||
| BRPI0800957-0A BRPI0800957A2 (pt) | 2008-04-04 | 2008-04-04 | vetores biológicos compreendendo o gene max, método de produção dos mesmos, método de expressão do gene max nas células e método de terapia gênica citoprotetora |
| PCT/BR2009/000093 WO2009121157A1 (en) | 2008-04-04 | 2009-04-03 | Vectors containing the max gene |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011516047A JP2011516047A (ja) | 2011-05-26 |
| JP2011516047A5 true JP2011516047A5 (enExample) | 2012-05-31 |
Family
ID=41134762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011502198A Pending JP2011516047A (ja) | 2008-04-04 | 2009-04-03 | Ｍａｘ遺伝子含有ベクター |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20110086090A1 (enExample) |
| JP (1) | JP2011516047A (enExample) |
| BR (1) | BRPI0800957A2 (enExample) |
| WO (1) | WO2009121157A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012158757A1 (en) * | 2011-05-16 | 2012-11-22 | The Trustees Of The University Of Pennsylvania | Proviral plasmids for production of recombinant adeno-associated virus |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5302519A (en) * | 1991-09-09 | 1994-04-12 | Fred Hutchinson Cancer Research Center | Method of producing a Mad polypeptide |
| US5512473A (en) * | 1993-01-29 | 1996-04-30 | Brent; Roger | Max-interacting proteins and related molecules and methods |
| US5827702A (en) * | 1994-10-31 | 1998-10-27 | Genentech, Inc. | Ocular gene therapy |
| US5811298A (en) * | 1996-02-29 | 1998-09-22 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Rep-max protein having anti-oncogenic activity and uses thereof |
| US6521225B1 (en) * | 1996-09-06 | 2003-02-18 | Chiron Corporation | AAV vectors |
| US6696423B1 (en) * | 1997-08-29 | 2004-02-24 | Biogen, Inc. | Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta |
| CA2303768C (en) * | 1997-09-19 | 2009-11-24 | The Trustees Of The University Of Pennsylvania | Methods and vector constructs useful for production of recombinant aav |
| US6683058B1 (en) * | 1998-04-15 | 2004-01-27 | Regents Of The University Of California | Methods for therapy of neurodegenerative disease of the brain |
| US6521255B2 (en) * | 2000-01-13 | 2003-02-18 | Osmotica Corp. | Osmotic device containing ranitidine and a prokinetic agent |
| US6998118B2 (en) * | 2001-12-21 | 2006-02-14 | The Salk Institute For Biological Studies | Targeted retrograde gene delivery for neuronal protection |
| US7186699B2 (en) * | 2003-06-03 | 2007-03-06 | Cell Genesys, Inc. | Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
| AU2004262369A1 (en) * | 2003-07-29 | 2005-02-10 | Bristol-Myers Squibb Company | Biomarkers of cyclin-dependent kinase modulation |
| US20050287519A1 (en) * | 2004-05-12 | 2005-12-29 | Merchiers Pascal G | Methods, compositions and compound assays for inhibiting amyloid-beta protein production |
-
2008
- 2008-04-04 BR BRPI0800957-0A patent/BRPI0800957A2/pt not_active Application Discontinuation
-
2009
- 2009-04-03 WO PCT/BR2009/000093 patent/WO2009121157A1/en not_active Ceased
- 2009-04-03 US US12/936,352 patent/US20110086090A1/en not_active Abandoned
- 2009-04-03 JP JP2011502198A patent/JP2011516047A/ja active Pending
-
2012
- 2012-11-21 US US13/683,632 patent/US20130184332A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Gene therapy for ocular diseases | |
| Nowakowski et al. | Genetic engineering of stem cells for enhanced therapy | |
| Gorell et al. | Gene therapy for skin diseases | |
| US20200299686A1 (en) | Methods and Compositions for Engineering Synthetic Bioswitches for Remote Control of Biological Activity | |
| US20230158114A1 (en) | Methods for the treatment of inflammatory joint disease | |
| JP2020505390A (ja) | Ｃｒｉｓｐｒ治療薬を送達するためのウイルスベクターとしてのレンチウイルスおよび非組み込みレンチウイルス | |
| EP4277987A1 (en) | Compositions for and methods of engineering the transcriptome | |
| US20200095586A1 (en) | Compositions and methods of treatment for lytic and lysogenic viruses | |
| JP2018509154A5 (enExample) | ||
| WO2018017925A1 (en) | Targeting lytic and latent herpes simplex virus 1 infection with crispr/cas9 | |
| JP2003189887A5 (enExample) | ||
| Zhang et al. | Advancement and prospects of tumor gene therapy | |
| US20240240179A1 (en) | Therapy for treatment of prader-willi syndrome | |
| CN100429316C (zh) | 一种重组腺病毒及其应用 | |
| Haritha et al. | Gene therapy–A review | |
| JP2015505535A5 (enExample) | ||
| Alavi et al. | Novel approaches and limitations in viral gene therapy of cancer diseases | |
| KR20250167670A (ko) | 초극소 역위 말단 반복(itr) 서열 및 그의 용도 | |
| Braun | History of Gene Therapy | |
| Thakur et al. | Gene therapy in India-current status | |
| Bi | How to Deliver Cas9 into Brain | |
| McMenamin | Translational benefits of gene therapy to date | |
| BANKOLE | PHYSIOLOGICAL BASIS OF GENE THERAPY IN CANCER MANAGEMENT | |
| Kurapova et al. | VIRAL VECTORS FOR DELIVERING GENE MATERIAL INTO CELLS AND THEIR APPLICATION IN NEUROBIOLOGY | |
| RU2003111095A (ru) | Рекомбинантная плазмидная днк pcdna-tci, обеспечивающая экспрессию искусственного гена tci в клетках эукариот, и рекомбинантный аттенуированный штамм бактерий salmonella enteritidis e-23/pcdna-tci как кандидат для конструирования живой днк-вакцины против вируса иммунодефицита человека |